# South Korea Sacroiliitis Treatment Market > South Korea Sacroiliitis Treatment Market Research Report By Type (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation) and By End-user (Hospitals, Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.43% - **2024:** $ 1,150 Million - **2025:** $ 1,361.94 Million - **2035:** $ 7,390 Million - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) **Report ID:** MRFR/HC/52187-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-sacroiliitis-treatment-market-53949 --- ## Market Summary ## **South Korea Sacroiliitis Treatment Market Overview** As per MRFR analysis, the South Korea Sacroiliitis Treatment Market Size was estimated at 779.05 (USD Million) in 2023.The South Korea Sacroiliitis Treatment Market is expected to grow from 922.4(USD Million) in 2024 to 2,812 (USD Million) by 2035. The South Korea Sacroiliitis Treatment Market CAGR (growth rate) is expected to be around 10.665% during the forecast period (2025 - 2035) **Key South Korea Sacroiliitis Treatment Market Trends Highlighted** The treatment of sacroiliitis is changing in South Korea as a result of multiple important market factors. The need for efficient treatment alternatives has increased due to the rising incidence of inflammatory diseases, including autoimmune disorders. More sacroiliitis cases are being caused by lifestyle-related health problems, in particular, which is forcing medical professionals to concentrate on cutting-edge treatment approaches. Additionally, the focus on early diagnosis using cutting-edge imaging methods has been crucial in enabling prompt patient interventions, which has improved results in the long run. The growth of biologic medicines and customized medicine strategies are two potential avenues for investigation in the South Korean market for sacroiliitis treatment. There is a great chance to create new drugs that target particular sacroiliitis pathways as South Korea's pharmaceutical sector develops. Furthermore, more cooperation between medical facilities, academic institutions, and pharmaceutical firms may result in the quick launch of novel therapies. This might be in line with the South Korean government's programs to improve healthcare and encourage medical technology research. Recent trends show an increasing preference for non-pharmacological treatments like physical therapy and lifestyle changes, as well as minimally invasive surgeries. Patients in South Korea are demanding more holistic care methods as they become more knowledgeable about their health. Access to treatment choices has also been improved by the growing popularity of telemedicine integration in the management of chronic illnesses. The market for sacroiliitis treatments is evolving to satisfy patients' evolving needs as South Korea's healthcare infrastructure continues to grow, guaranteeing higher-quality services and more patient satisfaction. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Sacroiliitis Treatment Market Drivers** **Increasing Prevalence of Autoimmune Diseases** The South Korea [Sacroiliitis Treatment Market](../../../reports/sacroiliitis-treatment-market-6590) is significantly driven by the rising prevalence of autoimmune diseases, especially ankylosing spondylitis, which is closely linked to sacroiliitis. According to the Korea Centers for Disease Control and Prevention, there has been a reported increase in autoimmune disorders among the Korean population by approximately 15% in the last five years. This growth is accompanied by heightened awareness and diagnosis rates due to the efforts of established organizations such as the Korean Society of Rheumatology, which actively promotes research and awareness on these conditions. As more individuals are diagnosed and seek effective treatment options, the demand for sacroiliitis treatments is likely to rise, reflecting a direct correlation between the prevalence of autoimmune diseases and market growth in South Korea. **Advancements in Treatment Technology** Technological advancements in treatment options, such as biologics and personalized medicine, are significantly contributing to the growth of the South Korea Sacroiliitis Treatment Market. The Ministry of Health and Welfare in South Korea has recognized and promoted the use of targeted therapies, which have shown to improve treatment effectiveness for sacroiliitis patients. For instance, the introduction of biologic drugs has revolutionized management protocols. Reports show that biologics have led to a 25% improvement in patient outcomes. This trend, backed by the continuous investment in Research and Development by pharmaceutical companies like Celltrion and Hanmi Pharmaceutical, plays a crucial role in expanding the market landscape. **Growing Aging Population** The increasing aging population in South Korea is another vital driver for the South Korea Sacroiliitis Treatment Market. Statistics from the Korean Statistical Information Service indicate that the proportion of elderly individuals has risen to nearly 15% of the total population. This demographic trend is associated with a higher incidence of degenerative diseases, including conditions that lead to or worsen sacroiliitis. With a rise in age-related health issues, the government has been amplifying healthcare policies and funding for effective treatments, causing a step up in the demand for sacroiliitis treatment options.The combination of an aging society and supportive health policies indicates significant growth potential for the market. **Increased Awareness and Patient Education** Enhanced awareness and patient education regarding sacroiliitis and related conditions are pivotal factors driving the South Korea Sacroiliitis Treatment Market. Campaigns led by organizations such as the Korean Rheumatism Society aim at educating the public on the importance of early diagnosis and treatment options available for sacroiliitis. Surveys indicate that about 60% of the population remains unaware of the condition and its implications, which points towards substantial opportunities for growth through awareness initiatives. Government support for these educational programs is increasingly evident, as proactive health campaigns are designed to encourage consultations and treatment for sacroiliitis, ultimately leading to an expansion of the treatment market in the region. **South Korea Sacroiliitis Treatment Market Segment Insights** **Sacroiliitis Treatment Market Type Insights** The South Korea Sacroiliitis Treatment Market is comprised of various treatment modalities classified by Type, which include Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, and Electrical Stimulation. This diverse array of treatment options is structured to address the varying severity and manifestations of sacroiliitis, reflecting a comprehensive approach to pain management. Medications, particularly non-steroidal anti-inflammatory drugs (NSAIDs), are widely used as the first line of treatment for pain relief, thereby forming a critical part of the market as they help manage symptoms effectively and improve the quality of life for patients. Joint Injections, which can deliver corticosteroids directly to the affected joint, have gained significance for quickly alleviating chronic pain associated with sacroiliitis, making them an important alternative for those who do not respond well to oral medications. Meanwhile, Joint Fusion is notable for its effectiveness in cases where structural correction is deemed necessary to relieve pain over the long term. This surgical option has seen a rise in interest due to ongoing advancements in minimally invasive techniques, aligning well with the growing trend towards outpatient care in South Korea. On the other hand, Radiofrequency Denervation offers patients a unique solution by using thermal energy to interrupt pain pathways, indicating a shift towards less invasive, yet highly effective, alternatives for those with persistent pain. Finally, Electrical Stimulation has emerged as a modern treatment avenue that not only addresses pain but also enhances functional recovery, attracting interests from both patients and healthcare providers alike. Together, these types underpin the South Korea Sacroiliitis Treatment Market, reflecting its multifaceted nature and the demand for tailored treatment options to address this challenging condition effectively. The continued development and incorporation of these treatments will likely contribute to market growth and evolution, responding to changes in patient needs and technological advancements within the sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Sacroiliitis Treatment Market****End-use****r Insights** The South Korea Sacroiliitis Treatment Market, particularly focusing on the End-user segment, reflects a dynamic landscape characterized by varied care settings. Hospitals play a crucial role as they are often the primary source for comprehensive medical care, enabling patients to receive advanced treatment through specialized teams. Clinics also contribute significantly to the market, offering outpatient services that provide more accessible treatment options for patients managing sacroiliitis. These facilities enable patients to receive timely interventions, promoting better health outcomes. Additionally, other care settings expand the array of treatment approaches available, catering to diverse patient needs. The South Korean government emphasizes improving healthcare access and enhancing the efficiency of clinical services, presenting a favorable environment for growth. The technological advancements and the rise of telemedicine further empower these End-users to adapt to changing patient demands. The South Korea Sacroiliitis Treatment Market revenue is influenced by these evolving dynamics in the healthcare ecosystem, demonstrating opportunities for innovative treatment options and patient management strategies. Overall, this segment is a critical component for adapting to the increasing prevalence of sacroiliitis while addressing the specific care needs of the population. **South Korea Sacroiliitis Treatment Market Key Players and Competitive Insights** The South Korea Sacroiliitis Treatment Market is experiencing a significant evolution driven by increasing prevalence of sacroiliitis among the population, heightened awareness about chronic inflammatory diseases, and advancements in medical technology. This market encompasses a wide array of treatments, including pharmacological therapies and innovative techniques that support pain management and improvement of functional mobility for affected individuals. The competitive landscape features a mix of established healthcare companies, specialty clinics, and hospitals, each striving to enhance patient care through cutting-edge solutions and comprehensive services. With a robust healthcare infrastructure and a growing emphasis on research and development, the South Korean market is positioned to foster rich competitive dynamics that can improve treatment outcomes. Medytox stands out in the South Korea Sacroiliitis Treatment Market with its commitment to innovation and high-quality therapeutic solutions. The company has established a significant presence through its diverse portfolio of products designed to treat sacroiliitis and other related inflammatory conditions. Medytox leverages its strong research and development framework to develop proprietary formulations that promote efficacy and safety in sacroiliitis treatment. The strength of Medytox lies in its ability to utilize advanced biopharmaceutical technologies, which allows them to respond effectively to the evolving treatment landscape. The company maintains strategic collaborations with local healthcare providers and research institutions, enhancing its ability to stay ahead of competitive pressures and fulfill the growing needs of patients suffering from sacroiliitis. Severance Hospital is a prominent healthcare institution in South Korea, renowned for its comprehensive approach to treating sacroiliitis among other medical conditions. This facility provides a range of key services, including specialized diagnostic techniques, personalized treatment plans, and access to the latest medical technologies. Severance Hospital is unique in its integration of advanced clinical practices with patient-centered care, which positions the hospital as a leader in managing chronic pain and inflammation. The institution benefits from a strong reputation built on research, evidence-based treatments, and an experienced team of healthcare professionals. Through various partnerships and collaborations, Severance Hospital is continually enhancing its capabilities, leading to improved patient outcomes. Its strategic efforts in research as well as its commitment to community health contribute significantly to its standing in the South Korea Sacroiliitis Treatment Market, further driving growth and innovation in therapies for patients. **Key Companies in the South Korea Sacroiliitis Treatment Market Include** - Medytox - Severance Hospital - SK Chemicals - Samsung Biologics - Korea United Pharm - Celltrion - Genexine - LG Chem - JW Pharmaceutical - Korean Vaccine - Hanmi Pharmaceutical - Daewoong Pharmaceutical - Asan Medical Center - Ildong Pharmaceutical **South Korea Sacroiliitis Treatment****Market****Developments** In the South Korea Sacroiliitis Treatment Market, several recent developments are noteworthy. Companies like Medytox and SK Chemicals are focusing on innovative therapies aimed at alleviating symptoms associated with sacroiliitis, which is seeing rising patient interest due to an increasing prevalence of autoimmune diseases in the region. In August 2023, Samsung Biologics announced plans to enhance its biologics manufacturing capacity to better support the development of treatments for various inflammatory diseases, including sacroiliitis. Meanwhile, in October 2023, Asan Medical Center launched a specialized clinic dedicated to treating inflammatory arthritis, catering specifically to patients with sacroiliitis. In terms of mergers and acquisitions, a significant development occurred in July 2023 when Celltrion acquired a local biotech firm to boost its capabilities in developing next-generation therapies for inflammatory conditions, which may include sacroiliitis. The market has also seen growth in valuations across firms such as Hanmi Pharmaceutical and JW Pharmaceutical, showing a positive market trajectory that reflects a heightened focus on Research and Development for new treatment options. The South Korean government continues to support biotechnology, fueling investment and innovation in therapeutic solutions for sacroiliitis, amid increasing demand for effective treatments. **South Korea Sacroiliitis Treatment Market Segmentation Insights** **Sacroiliitis Treatment Market Type****Outlook** - Medications - Joint Injections - Joint Fusion - Radiofrequency Denervation - Electrical Stimulation **Sacroiliitis Treatment Market****End-use****r****Outlook** - Hospitals - Clinics - Others ## Market Drivers ### Advancements in Treatment Modalities Innovations in treatment modalities are significantly influencing the sacroiliitis treatment market. The introduction of new pharmacological agents, including biologics and targeted therapies, has transformed the landscape of treatment options available. These advancements not only improve patient outcomes but also enhance the overall efficacy of treatment protocols. In South Korea, the approval of novel therapies has led to increased competition among pharmaceutical companies, driving down costs and making treatments more accessible. Additionally, the integration of personalized medicine approaches is likely to optimize treatment plans, catering to individual patient needs. This evolution in treatment strategies is expected to bolster the market, as healthcare providers adopt more effective and tailored solutions. ### Increasing Prevalence of Sacroiliitis The rising incidence of sacroiliitis in South Korea is a crucial driver for the sacroiliitis treatment market. Recent studies indicate that inflammatory diseases, including sacroiliitis, are becoming more common, particularly among the aging population. This demographic shift is likely to increase the demand for effective treatment options. As healthcare providers recognize the need for targeted therapies, the market is expected to expand. Furthermore, the prevalence of conditions such as ankylosing spondylitis, which is closely associated with sacroiliitis, further contributes to this trend. The growing awareness of these conditions among both patients and healthcare professionals is likely to enhance the market's growth trajectory, as more individuals seek appropriate medical interventions. ### Rising Awareness and Education Initiatives The growing awareness of sacroiliitis and related conditions is a significant driver for the sacroiliitis treatment market. Educational initiatives aimed at both healthcare professionals and the general public are crucial in promoting understanding of the disease. Increased awareness leads to earlier diagnosis and treatment, which is essential for effective management. In South Korea, various organizations are actively working to disseminate information about sacroiliitis, its symptoms, and treatment options. This heightened awareness is likely to result in more patients seeking medical advice, thereby increasing the demand for treatment. As patients become more informed, they are more likely to engage in discussions with healthcare providers about their treatment options, further stimulating market growth. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies is an essential driver of the sacroiliitis treatment market. In South Korea, the government has established frameworks that encourage the development and approval of new treatment options. This supportive regulatory environment is likely to expedite the introduction of advanced therapies, including biologics and novel small molecules. As regulatory bodies streamline the approval process, pharmaceutical companies are more inclined to invest in research and development for sacroiliitis treatments. This trend not only enhances the availability of effective therapies but also fosters competition within the market. Consequently, patients benefit from a wider array of treatment options, which may lead to improved health outcomes and increased market growth. ### Growing Investment in Healthcare Infrastructure The ongoing investment in healthcare infrastructure in South Korea is a pivotal driver for the sacroiliitis treatment market. The government has been actively enhancing healthcare facilities and services, which facilitates better access to diagnostic and treatment options for patients suffering from sacroiliitis. Increased funding for research and development in the field of rheumatology is also noteworthy, as it fosters innovation and the introduction of new therapies. As healthcare systems become more robust, the likelihood of early diagnosis and effective management of sacroiliitis increases, thereby expanding the market. Furthermore, improved healthcare access is expected to lead to higher patient engagement and adherence to treatment regimens, ultimately benefiting the market. ## Future Outlook The [Sacroiliitis Treatment Market](https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590) is projected to grow at an 18.43% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in biologics and targeted therapies for enhanced efficacy - Expansion of patient education programs to improve treatment adherence By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Medications (Largest) vs. Joint Injections (Fastest-Growing) In the South Korea sacroiliitis treatment market, the segment for medications dominates the landscape, holding a significant market share due to their wide acceptance and established effectiveness among healthcare providers. Joint injections, while slightly smaller in market share, are rapidly gaining traction, particularly as patients seek more targeted and immediate relief from symptoms. This dynamic creates a diverse landscape where both segments cater to specific patient needs and treatment preferences. Growth trends reveal that the demand for medications remains robust, fueled by ongoing research and advancements in pharmacology, while the joint injections segment is witnessing a surge driven by increased awareness about alternative therapies and patient-centered approaches. The rising prevalence of sacroiliitis and a focus on minimally invasive procedures are key trends shaping this market. Overall, innovations and improvements in treatment efficacy are expected to propel these segments further in the coming years. Medications (Dominant) vs. Joint Injections (Emerging) Medications serve as the dominant segment within the South Korea sacroiliitis treatment market, offering a broad range of options from anti-inflammatory drugs to pain relievers that are well-integrated into clinical practice. Their widespread recognition among physicians contributes to their prevalent usage. On the other hand, joint injections represent an emerging alternative with growing appeal; they promise targeted relief and are being increasingly recommended for patients seeking more direct interventions to manage pain and inflammation. As healthcare providers emphasize personalized treatment plans, the interest in joint injections is expected to rise, driven by their ability to deliver rapid results and enhanced patient satisfaction. This positioning of both segments suggests a balanced approach to treatment strategies in the market. ### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the South Korea sacroiliitis treatment market, hospitals hold the largest market share, attributed to their comprehensive capabilities in handling severe cases and offering advanced treatment options. Clinics, while smaller in market share, are gaining traction due to the rising preference for outpatient care and accessibility to specialized services. The presence of these two segments illustrates a dichotomy between established healthcare facilities and emerging alternatives that cater to patient needs more flexibly. The growth trends within this segment indicate a shift towards more outpatient services, with clinics seeing rapid expansion. Factors such as increasing awareness of sacroiliitis treatment options, improved patient outcomes, and a shift in preference towards less invasive treatment methods drive this growth. Furthermore, the integration of technologies in clinics enhances service delivery, making them an attractive option for patients who prioritize convenience and efficiency. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals serve as the dominant force in the South Korea sacroiliitis treatment market, offering a wide range of services and treatments that address intricate cases. Their ability to provide comprehensive care, including diagnostic imaging and surgical interventions, places them at the forefront of patient choice. On the other hand, clinics represent an emerging segment, appealing to patients through convenience and personalized care. They often provide quicker access to specialists and tend to have shorter waiting times, making them highly desirable for individuals seeking immediate treatment. As both segments evolve, the competition may foster improvements in service quality and patient satisfaction across the market spectrum. ## Competitive Benchmarking The sacroiliitis treatment market exhibits a dynamic competitive landscape, characterized by a blend of established pharmaceutical giants and emerging players. Key growth drivers include an increasing prevalence of autoimmune diseases, heightened awareness of chronic pain management, and advancements in biologic therapies. Major companies such as AbbVie Inc (US), Johnson & Johnson (US), and Novartis AG (CH) are strategically positioned to leverage these trends. AbbVie Inc (US) focuses on innovation through its robust pipeline of biologics, while Johnson & Johnson (US) emphasizes regional expansion and partnerships to enhance its market presence. Novartis AG (CH) appears to be investing heavily in digital transformation initiatives, which collectively shape a competitive environment that is increasingly reliant on technological advancements and strategic collaborations.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of South Korea's advanced manufacturing capabilities. The market structure is moderately fragmented, with a few dominant players exerting considerable influence. This fragmentation allows for niche players to emerge, yet the collective strength of key players like Pfizer Inc (US) and Roche Holding AG (CH) ensures that competition remains robust and innovation-driven. In October AbbVie Inc (US) announced a strategic partnership with a local biotech firm to enhance its research capabilities in the region. This collaboration is expected to accelerate the development of novel therapies for sacroiliitis, indicating AbbVie's commitment to localized innovation and responsiveness to market needs. Such partnerships may enhance AbbVie's competitive edge by integrating local insights into their global strategy. In September Johnson & Johnson (US) launched a new digital health platform aimed at improving patient engagement and treatment adherence for sacroiliitis patients. This initiative underscores the company's focus on digital transformation, which is likely to enhance patient outcomes and foster loyalty in a competitive market. By leveraging technology, Johnson & Johnson positions itself as a forward-thinking leader in patient-centric care. In August Novartis AG (CH) expanded its clinical trial program for a promising new biologic treatment for sacroiliitis, reflecting its commitment to innovation and research. This expansion not only strengthens Novartis's product pipeline but also signals its intent to capture a larger market share in the treatment of inflammatory diseases. The strategic importance of this move lies in its potential to address unmet medical needs and differentiate Novartis in a crowded marketplace. As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development and patient management. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in the evolving sacroiliitis treatment market. ## Recent News & Developments In the South Korea Sacroiliitis Treatment Market, several recent developments are noteworthy. Companies like Medytox and SK Chemicals are focusing on innovative therapies aimed at alleviating symptoms associated with sacroiliitis, which is seeing rising patient interest due to an increasing prevalence of autoimmune diseases in the region. In August 2023, Samsung Biologics announced plans to enhance its biologics manufacturing capacity to better support the development of treatments for various inflammatory diseases, including sacroiliitis. Meanwhile, in October 2023, Asan Medical Center launched a specialized clinic dedicated to treating inflammatory arthritis, catering specifically to patients with sacroiliitis. In terms of mergers and acquisitions, a significant development occurred in July 2023 when Celltrion acquired a local biotech firm to boost its capabilities in developing next-generation therapies for inflammatory conditions, which may include sacroiliitis. The market has also seen growth in valuations across firms such as Hanmi Pharmaceutical and JW Pharmaceutical, showing a positive market trajectory that reflects a heightened focus on Research and Development for new treatment options. The South Korean government continues to support biotechnology, fueling investment and innovation in therapeutic solutions for sacroiliitis, amid increasing demand for effective treatments. ## Report Scope | MARKET SIZE 2024 | 1150.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1361.94(USD Million) | | MARKET SIZE 2035 | 7390.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.43% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) | | Segments Covered | Type, End-User | | Key Market Opportunities | Emerging biologics and personalized therapies enhance treatment options in the sacroiliitis treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory adaptations in the sacroiliitis treatment market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the South Korea sacroiliitis treatment market?** A: The market valuation was $1150.0 Million in 2024. **Q: What is the projected market size for the South Korea sacroiliitis treatment market by 2035?** A: The market is expected to reach $7390.0 Million by 2035. **Q: What is the expected CAGR for the South Korea sacroiliitis treatment market during 2025 - 2035?** A: The expected CAGR is 18.43% during the forecast period. **Q: Which companies are the key players in the South Korea sacroiliitis treatment market?** A: Key players include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, Sanofi S.A., and UCB S.A. **Q: What are the main treatment types available in the South Korea sacroiliitis treatment market?** A: Main treatment types include Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, and Electrical Stimulation. **Q: How much revenue did the Medications segment generate in 2024?** A: The Medications segment generated $460.0 Million in 2024. **Q: What is the revenue projection for Joint Injections by 2035?** A: The revenue for Joint Injections is projected to reach $1500.0 Million by 2035. **Q: What are the end-user segments in the South Korea sacroiliitis treatment market?** A: End-user segments include Hospitals, Clinics, and Others. **Q: What was the revenue generated by Hospitals in 2024?** A: Hospitals generated $460.0 Million in revenue in 2024. **Q: How does the revenue of the Clinics segment compare to that of Hospitals in 2024?** A: Clinics also generated $460.0 Million, matching the revenue of Hospitals in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-sacroiliitis-treatment-market-53949*